Revive Therapeutics Ltd.

PNK:RVVTF

$0.009 USD

$0.0 (9.76%)

Volume
3K
Average Volume
467.61K
Market Capitalization
$3.77M
P/E Ratio
-0.74
Dividend Yield
0.00%
Price Target
$
Year High
$0.04
Year Low
$0.01
Payout Ratio
$0.00
Current Ratio
$0.34

Industry, Sector & symbol

Stock Exchange Other OTC
CEO Mr. Michael Frank
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Current Symbol RVVTF
CUSIP None
CIK None
Web https://www.revivethera.com
Phone 888-901-0036
Currency USD
Employees 3
Country CA

Liquidity

Debt-to-Equity Ratio 0.00
Payout Ratio 0.00
Current Ratio 0.34
Quick Ratio 0.34
Cash Ratio 0.25

Sales & Book Value

Annual Sales $-
Price / Sales 0.00
Cash Flow -0.01
Price / Cash Flow -1.27
Price / Book 0.58

Price Target and Rating

Average Stock Price Forecast $
High Stock Price Forecast $
Low Stock Price Forecast $
Forecast Upside/Downside %
Consensus Rating Sell
Rating Score(0-5) 2
Research Coverage 0 Analysts

Profitability

EPS (Most Recent Fiscal Year) $-0.0186
Trailing P/E Ratio -0.74
PEG Ratio 0.03
P/E Growth 0.03
Net Income $-6.32M
Net Margin 0.00%
Pretax Margin 0.00%
Return on Equity -61.00%
Return on Assets -52.83%

Financials Score

AltmanZ Score -10.04
Piotroski Score 2.00
Working Capital -2.18M
Total Assets 10.64M
Ebit -5.62M
Market Cap 3.77M
Total Liabilities 3.4M

Poll Results

About Revive Therapeutics Ltd. (PNK:RVVTF) Stock

Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics for rare disorders and infectious diseases. The company offers cannabinoid pharmaceutical portfolio that focuses on rare inflammatory diseases. It is developing Bucillamine, which is in Phase 3 clinical study for the treatment of infectious diseases, including influenza and COVID-19; Psilocybin that is in Phase 1 clinical study for treating methamphetamine use disorder; Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases; and cannabidiol for treating autoimmune hepatitis and ischemia and reperfusion injury from organ transplantation. Revive Therapeutics Ltd. has research collaboration agreements with PharmaTher Inc. fo ... r the development of psilocybin in the treatment of cancer and the discovery of other uses of undisclosed psychedelic compounds; North Carolina State University for the development of a biosynthetic version of psilocybin based on a natural biosynthesis enzymatic platform; the University of California, San Francisco to explore the use of Bucillamine as a treatment for severe COVID-19; University of Health Sciences Antigua for the clinical research of psychedelics; and PharmaTher for the development of psilocybin microneedle patch. The company was incorporated in 2012 and is headquartered in Toronto, Canada.

Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke

2024-11-12 07:45:00

TORONTO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, medical countermeasures and rare disorders, today announced the publication of a scientific article demonstrating the potential of psilocybin as a novel therapeutic approach in stroke. The publication, entitled, “Neuroprotective effects of psilocybin in a rat model of stroke,” is published in BMC Neuroscience and is available here.

Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure

2024-07-02 13:58:00

TORONTO, July 02, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders, announced today an update on the research study evaluating Bucillamine as a potential treatment for nerve agent exposure, in partnership with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence. The DRDC is investigating pharmacological compounds, including Bucillamine, that can mitigate nerve agent induced brain injury. Control studies have been initiated and the DRDC expects to evaluate the data this month. Treatment studies will follow after the conclusion of the control group evaluation. The research study is expected to be completed in August 2024.

Revive Therapeutics Provides Update on FDA Type C Meeting for Clinical Study of Bucillamine to Treat Long COVID

2024-06-12 09:05:00

TORONTO, June 12, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders, announced today an update on the Type C meeting written responses received by the Company from the U.S. Food & Drug Administration (“FDA”) for the evaluation of a proposed clinical study of Bucillamine, an oral thiol-based drug with anti-inflammatory and antiviral properties, as a potential treatment for Long COVID (the “Study”).

Revive Therapeutics Provides Update From FDA Meeting for Long COVID Diagnostic Product

2024-06-10 07:30:00

TORONTO, June 10, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders, announced today an update on the meeting written responses received by the Company from the U.S. Food & Drug Administration (“FDA”) of the Revive LC POC Lateral Flow Test Kit (the “Product”) for feedback on the classification, development and regulatory submission strategy for a point-of-care in vitro diagnostic device that aids in the detection of post COVID-19 conditions. The FDA has determined that the Product should follow the De Novo regulatory pathway, and the Company would be required to conduct a clinical study for the De Novo submission for possible approval.

Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID

2024-04-23 07:00:00

TORONTO, April 23, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders, announced today that the U.S. Food & Drug Administration (“FDA”) has granted the Company's Type C meeting request for the evaluation of a proposed clinical study of Bucillamine, an oral thiol-based drug with anti-inflammatory and antiviral properties, as a potential treatment for long COVID. The meeting date assigned by the FDA is June 9, 2024.

Frequently Asked Questions

What is the current Revive Therapeutics Ltd. (RVVTF) stock price?

Revive Therapeutics Ltd.(PNK:RVVTF) stock price is $0.009 in the last trading session. During the trading session, RVVTF stock reached the peak price of $0.036 while $0.006 was the lowest point it dropped to. The percentage change in RVVTF stock occurred in the recent session was 9.76% while the dollar amount for the price change in RVVTF stock was $0.0.

RVVTF's industry and sector of operation?

The PNK listed RVVTF is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.

Who are the executives of RVVTF?

Dr. Onesmo Mpanju Ph.D. | Chief Regulatory Affairs Consultant
Mr. Carmelo Marrelli ACIS, B.Comm., C.A., C.P.A., CGA, CPA | Chief Financial Officer
Dr. Kelly T. McKee Jr., M.D., M.P.H. | Chief Scientific Officer Consultant
Mr. Michael Frank | Chairman & Chief Executive Officer
|

How many employees does RVVTF have?

Number of RVVTF employees currently stands at 3. RVVTF operates from The Canadian Venture Building, Toronto, ON M5C 1P1, CA.

Link for RVVTF official website?

Official Website of RVVTF is: https://www.revivethera.com

How do I contact RVVTF?

RVVTF could be contacted at phone #888-901-0036 and can also be accessed through its website. RVVTF operates from The Canadian Venture Building, Toronto, ON M5C 1P1, CA.

How many shares of RVVTF are traded daily?

The average number of RVVTF shares traded daily for last 3 months was 467.61K.

What is the market cap of RVVTF currently?

The market value of RVVTF currently stands at $3.77M with its latest stock price at $0.009